标题/作者	年份
Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356	2017
Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 377 (19), 1813-1823	2017
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ... The Lancet Oncology 19 (11), 1480-1492	2018
Combined nivolumab and ipilimumab in melanoma metastatic to the brain HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ... New England Journal of Medicine 379 (8), 722-730	2018
Melanoma D Schadendorf, ACJ van Akkooi, C Berking, KG Griewank, R Gutzmer, ... The Lancet 392 (10151), 971-984	2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (5), 603-615	2018
Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Journal of Clinical Oncology 36 (1), 7	2018
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ... The Lancet Oncology 18 (7), 863-873	2017
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (10), 1315-1327	2018
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine L Cheng, A Lopez-Beltran, F Massari, GT MacLennan, R Montironi Modern Pathology 31 (1), 24-38	2018
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology DG Coit, JA Thompson, MR Albertini, C Barker, WE Carson, C Contreras, ... Journal of the National Comprehensive Cancer Network 17 (4), 367-402	2019
Long-term outcomes in patients with BRAF V600–mutant metastatic melanoma who received dabrafenib combined with trametinib GV Long, Z Eroglu, J Infante, S Patel, A Daud, DB Johnson, R Gonzalez, ... Journal of Clinical Oncology 36 (7), 667-673	2018
Therapeutic strategies to target RAS-mutant cancers MB Ryan, RB Corcoran Nature reviews Clinical oncology 15 (11), 709-720	2018
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma S Kakadia, N Yarlagadda, R Awad, M Kundranda, J Niu, B Naraev, ... OncoTargets and therapy 11, 7095	2018
The current state of molecular testing in the treatment of patients with solid tumors, 2019 WS El‐Deiry, RM Goldberg, HJ Lenz, AF Shields, GT Gibney, AR Tan, ... CA: a cancer journal for clinicians 69 (4), 305-343	2019
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials D Schadendorf, GV Long, D Stroiakovski, B Karaszewska, A Hauschild, ... European Journal of Cancer 82, 45-55	2017
Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study MK Callahan, H Kluger, MA Postow, NH Segal, A Lesokhin, MB Atkins, ... Journal of Clinical Oncology 36 (4), 391	2018
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, ... The Lancet Oncology 21 (9), 1234-1243	2020
Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma PA Ascierto, R Dummer, HJ Gogas, KT Flaherty, A Arance, M Mandala, ... European Journal of Cancer 126, 33-44	2020
Mechanisms and therapy for cancer metastasis to the brain F Franchino, R Rudà, R Soffietti Frontiers in oncology 8, 161	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。